This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Short Trade: Supernus IPO Lock-Up

BOSTON ( TheStreet) -- With the massive amount of attention surrounding the Facebook (FB) initial public offering, many new traders were introduced to the insider "lock up" -- the period of time, usually between three months and six months immediately following the IPO, during which insiders are not allowed to sell any of their shares. When the lock-up period ends, insiders are allowed to sell their shares into the open market.

Insider selling (or even fear of insider selling) upon a lock-up expiration can cause a stock to drop in value. Traders take note.

Supernus Pharmaceuticals (SUPN - Get Report), a recent specialty pharma IPO, has 10 million shares set to be unlocked on Wednesday. The lock-up on Supernus shares actually lifted Monday but was delayed due to the markets being closed for the past two days.

If Supernus insiders decide to take profits, the stock price could drop quickly. Supernus trades with an average daily volume of only 62k shares. I'm short Supernus, betting on just such a drop in the company's stock price.

Supernus went public on May 1 at $5 per share. Since the offering, the FDA has approved two Supernus products -- Trokendi XR, a once-daily extended release formulation of topiramate, and Oxtellar XR, a once-daily extended release formulation of oxcarbazepine was approved. Both Trokendi and Oxtellar are extended release versions of two widely available generic drugs.

Today, Supernus shares have more than doubled in value to $10.95, offering ample incentive for insiders to sell a good chunk of the 10 million shares freed from the lock up. Ten million shares may not sound like much, but the block represents nearly 40% of Supernus' float. Outside of the lock-up expiration, there are no near-term catalysts for Supernus to drive the stock higher.

I can't guarantee that Supernus insiders are going to sell their shares this week, but larger paper gains since the May IPO and a volatile stock price suggests we're going to see some selling pressure.

One noteworthy risk to be aware of: Supernus can delay the expiration of the insider share lock-up by 18 days due to earnings or a "material event." Oxtellar was approved on Oct. 22 but it's not clear if the company has deemed this to be a material event for the purposes of delaying the lock-up. If it is, the lock-up expiration could be pushed back to Nov. 9.

Disclosure: Messier is short Supernus.

Mark Messier is the founder of BioRunUp.com. Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profit in just 4 years. In April 2010, Messier founded the subscription-based stock-trading web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
SUPN $11.78 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs